Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5251-5262

  Nakajima, Yoshimi ^a   Takagi, Hitoshi ^a,b   Kakizaki, Satoru ^a   Horiguchi, Norio ^a   Sato, Ken ^a   Sunaga, Noriaki ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Apoptosis; Cholangiocarcinoma; Combination treatment; EGFR; Gefitinib; Gemcitabine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; MESSENGER RNA; METHYLCELLULOSE; MITOGEN ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, NUDE; QUINAZOLINES; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872520105     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Blechacz B, Komuta M, Roskams T and Gores GJ: Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 8: 512-522, 2011.
2. Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, Therneau TM, Roberts LR, Gores GJ and Kim WR: Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol 107: 1256-1262, 2012.
3. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC and Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut Aug 15, 2012. [Epub ahead of print].
4. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M and Kudo M: The Liver Cancer Study of Japan: Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 37: 676-691, 2007.
5. Vasilieva LE, Papadhimitriou SI and Dourakis SP: Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 11: 349-359, 2012.
6. Anderson CD, Pinson CW, Berlin J and Chari RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist 9: 43-57, 2004.
7. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD and Cameron JL: Perihilar cholangiocarcinoma: Postoperative radiotherapy does not improve survival. Ann Surg 221: 788-797, 1995.
8. Nastoupil LJ, Rose AC and Flowers CR: Diffuse large B-cell lymphoma: Current treatment approaches. Oncology 26: 488-495, 2012.
9. Agulnik M and Giel JL: Understanding Rechallenge and Resistance in the Tyrosine Kinase Inhibitor Era: Imatinib in Gastrointestinal Stromal Tumor. Am J Clin Oncol. Jul 3, 2012. [Epub ahead of print].
10. Ohanian M, Cortes J, Kantarjian H and Jabbour E: Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother 13 : 927-938, 2012.
11. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE and Holen KD: Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28: 3491-3497, 2010.
12. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, Zironi S, Depenni R, Fontana A, Del Giovane C, Luppi G and Conte P: Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial. Br J Cancer 102: 68-72, 2010.
13. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J and Erlichman C: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24: 3069-3074, 2006.
14. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK and Lim HY: Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13: 181-188, 2012.
15. Gores GJ: Cholangiocarcinoma. Current concepts and insights. Hepatology 37 : 961-969, 2003.
16. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM and Thorgeirsson SS: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142: 1021-1031, 2012.
17. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW and Gores GJ: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 41: 808-814, 2004.
18. Sirica AE: Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol 14: 7033-7058, 2008.
19. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka H, Kosuge T, Kasai S, Hirohashi S and Shibata T: Clinicopathological and prognostic significance of EGFR, VEGF and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425, 2008.
20. Ying JE, Zhu LM and Liu BX: Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 18: 736-745, 2012.
21. Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C and Bralet MP: Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72: 105-110, 2007.
22. Matsumoto K, Nagahara T, Okano J and Murawaki Y: The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 20: 863-872, 2008.
23. Sunaga N, Kohno T, Shinmura K, Saitoh T, Matsuda T, Saito R and Yokota J: OGG1 protein suppresses G:C - >T:A mutation in a shuttle vector containing 8-hydroxyguanine in human cells. Carcinogenesis 22: 1355-1362, 2001.
24. Takizawa D, Kakizaki S, Horiguchi N, Tojima H, Yamazaki Y, Ichikawa T, Sato K and Mori M: Histone deacetylase inhibitors induce cytochrome P450 2B by activating nuclear receptor constitutive androstane receptor. Drug Metab Dispos 38: 1493-1498, 2010.
25. Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H and Mori M: A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50 : 563-567, 2002.
26. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM and Carbone DP: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibition in lung cancer. Cancer Res 65: 226-235, 2005.
27. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Yoshitaka Fujii, Eck MJ, Sellers WR, Johnson BE and Meyeson M: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
28. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, Tanaka S, Suga T, Saito R, Ishizuka T, Dobashi K, Minna JD, Nakajima T and Mori M: Clinicopathological significance of the mutations of the epidermal growth factor receptor gene on patients with non-small cell lung cancer. Clin Cancer Res 11: 6816-6822, 2005.
29. Awale S, Lu J, Kalauni SK, Kurashima Y, Tezuka Y, Kadota S and Esumi H: Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 66: 1751-1757, 2006.
30. Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6 : 4885-4892, 2000.
31. Takizawa D, Kakizaki S, Horiguchi N, Yamazaki Y, Tojima H and Mori M: Constitutive active/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis. Carcinogenesis 32: 576-583, 2011.
32. Taïeb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P and Ducreux M: Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13 : 1192-1196, 2002.
33. Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, Doi R, Ikai I, Kitano T, Nishimura T, Yoshikawa K, Ishiguro H, Yanagihara K, Doi E, Teramukai S and Fukushima M: Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology 70: 358-365, 2006.
34. Nakajima T, Takayama T, Miyanishi K, Nobuoka A, Hayashi T, Abe T, Kato J, Sakon K, Naniwa Y, Tanabe H and Niitsu Y: Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. J Pharmacol Exp Ther 306 : 861-869, 2003.
35. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2: 225-235, 2005.
36. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, Housset C and Rosmorduc O: Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119: 2557-2566, 2006.
37. Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutras AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT and Kosmidis P: Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest 26: 784-793, 2008.
38. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS and Nyati MK: Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66: 981-988, 2006.